Frequency of Heparin-Platelet Factor 4 Antibodies among Patients with Acute Coronary Syndromes Presenting to the Emergency Department
| Autor: | Mary Kathryn Duncan, Alane Drexler, Jamie M. Walker, John L. Francis, Sarfraz Ahmad |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
business.industry Immunology Cell Biology Hematology Emergency department Heparin medicine.disease Biochemistry Asymptomatic Cardiac surgery Surgery Coronary artery disease Internal medicine medicine medicine.symptom Prospective cohort study business Complication Platelet factor 4 medicine.drug |
| Zdroj: | Blood. 104:2067-2067 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v104.11.2067.2067 |
| Popis: | Heparin is widely used to treat patients that present with acute coronary syndromes (ACS). A significant, albeit under-recognized complication of heparin therapy is heparin-induced thrombocytopenia (HIT), which is estimated to occur in 1–3% of patients. A significantly higher proportion (20–50%) of patients undergoing cardiac surgery and other invasive cardiology procedures develop an antibody against the heparin-platelet factor 4 (HPF4) complex. Most patients remain asymptomatic, but are nevertheless at risk for HIT with subsequent heparin exposure. Patients with severe coronary artery disease frequently have multiple hospital admissions, and heparin exposures. HPF4 antibodies are transient, and most will become undetectable three months after their initial formation. Therefore, patients with a recent history of hospitalization would be at greater risk of HIT on heparin re-exposure. We tested this hypothesis in a prospective study of patients with ACS presenting to the Emergency Department. We studied 230 patients presenting to the ED with ACS. Patients were stratified into Group 1 (having a recent [ |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|